Fluence Raises $3M in Seed Funding


Fluencya New York-based educational platform specializing in training and certification for psychedelic therapy and psychedelic integrative therapy, has completed a $3 million seed funding round.

Leading investors in the first close included JLS Fund, Palo Santo and Neo Kuma, with LearnStart, Evolve Ventures and Foundation, Iter Investments, Baroda Ventures, Matthew Emerman, Michael Cotton and Noah Levy completing the raise.

The company will use the funding to launch new psychedelic therapy courses, training and certificate programs, and to bolster the development of training software and the expansion of their online learning platform.

Founded in 2019 by Dr. Ingmar Gorman and Dr. Elizabeth Nielson, and also led by Michael Kuntz, Chief Operating Officer, Fluence is an expertise-driven educational platform that provides professional certification and training in psychedelic therapy and psychedelic integration. The company, which has trained nearly 1,000 practitioners over the past two years, works directly with licensed healthcare professionals and graduate students to advance clinical skills and knowledge, giving clinicians the tools to provide their patients an effective, compassionate and evidence-based psychedelic therapy and integrative service.

The company has also developed partnerships with leading drug developers including Beckley Psytech, Tryp Therapeutics, Clairvoyant Therapeutics and others to develop psychedelic-assisted psychotherapy manuals and customized training programs for clinical trial therapists. , and expand its capacity for future enterprise-level partnerships.

In preparation for the implementation of Measure 109 in Oregon in 2023 and the future licensing of psilocybin facilitators, Fluence is developing a psilocybin-assisted therapy program to meet Oregon Health Authority requirements and train clinicians to this professional skill.




Comments are closed.